➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Medtronic
Colorcon
Express Scripts
Dow

Last Updated: November 28, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,649,352

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,649,352
Title:High purity oritavancin and method of producing same
Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
Inventor(s): Rafai Far; Adel (Mount-Royal, CA), Krishna; Gopal (Parsippany, NJ), Ding; Min (Parsippany, NJ), Chemburkar; Sanjay R. (North Chicago, IL), Knable; Carl M. (North Chicago, IL), Petzel; James P. (North Chicago, IL), Pruyne; Julie J. (North Chicago, IL), Reamer; Douglas M. (North Chicago, IL)
Assignee: THE MEDICINES COMPANY (Parsippany, NJ) ABBVIE INC. (Chicago, IL)
Application Number:14/801,303
Patent Claims: 1. A pharmaceutical composition comprising an oritavancin drug substance preparation and one or more pharmaceutically acceptable excipients, wherein the oritavancin drug substance preparation has about 90% purity or greater by peak area relative to impurities 2-16, defined by peaks B-P of FIG. 2, respectively.

2. The pharmaceutical composition of claim 1, wherein the oritavancin drug substance preparation has about 95% purity or greater by peak area.

3. The pharmaceutical composition of claim 1, wherein the one or more pharmaceutically acceptable excipients are selected from the group consisting of mannitol, sorbitol, sucrose and trehalose.

4. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable excipient is mannitol.

5. The pharmaceutical composition of claim 1, wherein the ratio of the drug substance preparation to the one or more excipients is 2:1 by weight.

6. The pharmaceutical composition of claim 1, wherein the purity level of the oritavancin drug substance preparation is measured by HPLC.

7. The pharmaceutical composition of claim 6, wherein the purity level of the oritavancin drug substance preparation is measured by HPLC, and wherein the HPLC measurement utilizes a C18 reverse-phase stationary phase and a gradient of mobile phase B, which is phosphoric acid/water/acetonitrile/tetrahydrofuran at a ratio of about 1/1000/1500/25 (v/v/v/v), in mobile phase A, which is phosphoric acid/water/tetrahydrofuran at a ratio of about 1/1000/10 (v/v/v).

8. A pharmaceutical composition comprising an oritavancin drug substance preparation and one or more pharmaceutically acceptable excipients, wherein the oritavancin drug substance preparation has a maximum impurity level of not more than 4.8% by peak area of impurity 2 and impurity 10, defined by peaks B and J shown in FIG. 2, respectively.

9. The pharmaceutical composition of claim 8, wherein the oritavancin drug substance preparation has a maximum impurity level of not more than 3.0% by peak area.

10. The pharmaceutical composition of claim 8, wherein the oritavancin drug substance preparation has a maximum impurity level of not more than 1.9% by peak area of impurity 2 and 2.9% by peak area of impurity 10.

11. The pharmaceutical composition of claim 8, wherein the one or more pharmaceutically acceptable excipients are selected from the group consisting of mannitol, sorbitol, sucrose and trehalose.

12. The pharmaceutical composition of claim 8, wherein the pharmaceutically acceptable excipient is mannitol.

13. The pharmaceutical composition of claim 8, wherein the ratio of the drug substance preparation to the one or more excipients is 2:1 by weight.

14. The pharmaceutical composition of claim 8, wherein the purity level of the oritavancin drug substance preparation is measured by HPLC.

15. The pharmaceutical composition of claim 14, wherein the purity level of the oritavancin drug substance preparation is measured by HPLC, and wherein the HPLC measurement utilizes a C18 reverse-phase stationary phase and a gradient of mobile phase B, which is phosphoric acid/water/acetonitrile/tetrahydrofuran at a ratio of about 1/1000/1500/25 (v/v/v/v), in mobile phase A, which is phosphoric acid/water/tetrahydrofuran at a ratio of about 1/1000/10 (v/v/v).

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
McKesson
Colorcon
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.